SCHEMBL5446185

SCHEMBL5446185

O=C(Nc1ccccc1)Nc1ccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 18/20 0.81
ADRB1 P08588 17/20 0.81
ADRB3 P13945 16/20 0.81
KDM4E B2RXH2 2/20 0.80
MEN1 O00255 2/20 0.80
TP53 P04637 2/20 0.80
CYP3A4 P08684 2/20 0.80
MAPK1 P28482 2/20 0.80
KMT2A Q03164 2/20 0.80
HTR1A P08908 1/20 0.80
CHRM5 P08912 1/20 0.80
DRD2 P14416 1/20 0.80
ADRA2B P18089 1/20 0.80
DRD4 P21917 1/20 0.80
SLC6A2 P23975 1/20 0.80
FPR3 P25089 1/20 0.80
ADRA1D P25100 1/20 0.80
HTR1D P28221 1/20 0.80
HTR1B P28222 1/20 0.80
HTR2A P28223 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5446196 1.00 ADRB2 (0.81) ADRB2ADRB1ADRB3KDM4EMEN1
Acetic Acid SCHEMBL5450491 0.97 ADRB2 (0.85) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL927337 0.93 ADRB2 (0.80) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL927339 0.93 ADRB2 (0.80) ADRB2ADRB1ADRB3KDM4EMEN1
Acetic Acid SCHEMBL926381 0.91 ADRB2 (0.84) ADRB2ADRB1ADRB3
SCHEMBL5454004 0.90 ADRB2 (1.00) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL5454011 0.90 ADRB2 (1.00) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL5450390 0.90 ADRB2 (0.69) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL5450401 0.90 ADRB2 (0.69) ADRB2ADRB1ADRB3KDM4EMEN1
SCHEMBL5455554 0.89 ADRB2 (0.81) ADRB2ADRB1ADRB3KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249630-A1 Phenethanolamine derivatives for treatment of respiratory diseases GLAXO GROUP LIMITED (GB) 2007-10-25 US disclosed
US-20050209338-A1 Phenethanolamine derivatives for treatment of respiratory diseases GLAXO GROUP LIMITED (GB) 2005-09-22 US disclosed
EP-1478620-A1 PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES GLAXO GROUP LIMITED (GB) 2004-11-24 EP disclosed
WO-2003072539-A1 PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209338-A1 Phenethanolamine derivatives for treatment of respiratory diseases PHOSPHO1, PNMT, PEBP1 ADRB2 89/4885ADRB1 192/4885ADRB3 128/4885
US-20070249630-A1 Phenethanolamine derivatives for treatment of respiratory diseases PHOSPHO1, PNMT, PEBP1 ADRB2 89/4885ADRB1 192/4885ADRB3 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.